Paliperidone long-acting injections in Huntington’s Disease for motor and behavioural disturbances

Oral antipsychotics are used to treat motor and behavioural disturbances in Huntington’s disease (HD). However, patients with behavioural disturbances are often non-compliant, thus the oral route is inappropriate. The effects of antipsychotic long-acting injections (LAI) in HD are significantly underrepresented in literature. Paliperidone LAI (P-LAI), an atypical antipsychotic, has benefits over other antipsychotics LAI with its long dosing interval and no initial oral overlap, but has no documented cases for this indication. This case of a 45-year-old female highlights the use of P-LAI for severe aggression and chorea secondary to HD causing failed placement in assisted-care accommodation and mobility via an electronic-wheelchair. Three weeks after commencing treatment, she could walk unassisted, and displayed no aggression. After 10\ua0months, she still had significant improvements and resided in the same accommodation for 6\ua0months without any\ua0concern. Thus, this case suggests that P-LAI may be a treatment option for non-compliant HD patients